Maple Grove, MN & Taipei, Taiwan – July 23, 2025
Cutting-Edge Technology to Accelerate High-Volume Production; Mississauga Site to be
Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472),
Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472),
Tanvex BioPharma, Inc. (“Tanvex”), a contract development and manufacturing organization
Bora Biologics Announces Strategic Collaboration to Accelerate Key CMC Development
Bora Pharmaceuticals Announces Unveiling of New Multi-Purpose Small Molecule Site
Bora Pharmaceuticals Wins Dual Honors at the Taiwan MAPECT M&A
Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472),
Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472),
Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472),
